NEW ORLEANS, Aug. 28, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dimension Therapeutics, Inc. ("Dimension" or the "Company") (NASDAQ: DMTX) to REGENXBIO Inc. (NASDAQ: RGNX). Under the terms of the proposed transaction, shareholders of Dimension will receive only 0.1573 shares of REGENXBIO for each share of Dimension that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
206 Covington St.
Madisonville, LA 70447
View original content with multimedia:http://www.prnewswire.com/news-releases/dimension-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-dimension-therapeutics-inc-300510889.html
SOURCE Kahn Swick & Foti, LLC